DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on January 12, 2007; DOI: 10.1124/dmd.106.012336


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.012336v1
35/4/566    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mamidi, R. N.V.S.
Right arrow Articles by Meuldermans, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mamidi, R. N.V.S.
Right arrow Articles by Meuldermans, W.


Received for publication August 17, 2006.
Revised January 9, 2007.
Accepted for publication January 10, 2007.

Metabolism and excretion of RWJ-333369 in mice, rats, rabbits, and dogs

Rao N.V.S. Mamidi 1*, Geert Mannens 2, Pieter Annaert 2, Jan Hendrickx 2, Ivo Goris 2, Mark Bockx 2, Cor G.M. Janssen 2, Mark Kao 3, Michael F. Kelley 4, Willem Meuldermans 2

1 Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ, USA 2 Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium 3 Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ, USA 4 Johnson & Johnson Pharmaceutical Research & Development, PA, USA

* Address correspondence to: E-mail: smamidi1{at}prdus.jnj.com

Abstract

The in vivo metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-], a novel neuromodulator, were investigated in mice, rats, rabbits, and dogs after oral administration of 14C-RWJ-333369. Plasma, urine, and feces samples were collected, assayed for radioactivity, and profiled for metabolites. In almost all species, the administered radioactive dose was predominantly excreted in urine (>85%) with less than 10% in feces. Excretion of radioactivity was rapid and nearly complete at 96 h after dosing in all species. Unchanged drug excreted in urine was minimal (<2.3% of the administered dose) in all species. The primary metabolic pathways were O-glucuronidation (rabbit > mouse > dog > rat) of RWJ-333369 and hydrolysis of the carbamate ester followed by oxidation to 2-chloromandelic acid. The latter metabolite was subsequently metabolized in parallel to 2-chlorophenylglycine and 2-chlorobenzoic acid (combined hydrolytic and oxidative pathways: rat > dog > mouse > rabbit). Other metabolic pathways present in all species included chiral inversion in combination with O-glucuronidation and sulphate conjugation (either directly and/or following hydroxylation of RWJ-333369). Species-specific pathways, including N-acetylation of 2-chlorophenylglycine (mice, rats, and dogs) and arene oxidation followed by glutathione conjugation of RWJ-333369 (mice and rats), were more predominant in rodents than in other species. Consistent with human metabolism, multiple metabolic pathways and renal excretion were mainly involved in the elimination of RWJ-333369 and its metabolites in animal species. Unchanged drug was the major plasma circulating drug-related substance in the preclinical species and humans.


Key words: drug disposition, glucuronidation, glutathione conjugates, HPLC, mass spectrometry, metabolite identification, renal elimination





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.